menu
    • menu

    Find Acitretin manufacturers, exporters & distributors on PharmaCompass

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    16

    API Suppliers

    API Suppliers

    10

    USDMF

    US DMFs Filed

    5

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    3

    EU WC

    EU WC

    0

    KDMF

    KDMF

    7

    NDC API

    NDC API

    0

    VMF

    NDC API

    6

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 5,181

    MARKET PLACE

    8

    API

    3

    FDF

    3INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    84

    FDF Dossiers

    FDF Dossiers

    23

    FDA Orange Book

    FDA (Orange Book)

    38

    Europe

    Europe

    6

    Canada

    Canada

    4

    Australia

    Australia

    4

    South Africa

    South Africa

    9

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    2

    EDQM

    3

    USP

    0

    JP

    3

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    3

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    20,934,137

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    108 RELATED EXCIPIENT COMPANIES

    196EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 55079-83-9, Etretin, Soriatane, Neotigason, Acitretine, All-trans-acitretin
    Molecular Formula
    C21H26O3
    Molecular Weight
    326.4  g/mol
    InChI Key
    IHUNBGSDBOWDMA-AQFIFDHZSA-N
    FDA UNII
    LCH760E9T7
    Acitretin
    An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
    Acitretin is a Retinoid.
    1 2D Structure

    Acitretin

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
    2.1.2 InChI
    InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
    2.1.3 InChI Key
    IHUNBGSDBOWDMA-AQFIFDHZSA-N
    2.1.4 Canonical SMILES
    CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
    2.1.5 Isomeric SMILES
    CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC
    2.2 Other Identifiers
    2.2.1 UNII
    LCH760E9T7
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 13-cis-acitretin

    2. Acitretin, (z,e,e,e)-isomer

    3. Etretin

    4. Isoacitretin

    5. Isoetretin

    6. Neotigason

    7. Ro 10-1670

    8. Ro 101670

    9. Ro 13-7652

    10. Ro 137652

    11. Ro-10-1670

    12. Ro-13-7652

    13. Ro101670

    14. Ro137652

    15. Soriatane

    2.3.2 Depositor-Supplied Synonyms

    1. 55079-83-9

    2. Etretin

    3. Soriatane

    4. Neotigason

    5. Acitretine

    6. All-trans-acitretin

    7. Retinoid Etretin

    8. Ro 10-1670

    9. (2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic Acid

    10. Acitretina

    11. Acitretinum

    12. Tmmp

    13. Ro 10-1670/000

    14. 9-cis Acitretin

    15. (all-e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid

    16. 54757-46-9

    17. All-trans-3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic Acid

    18. Chebi:50173

    19. 2,4,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-e)-

    20. Ro-101670000

    21. Lch760e9t7

    22. Ro-10-1670/000

    23. Ncgc00163127-02

    24. Acitretine [french]

    25. Acitretinum [latin]

    26. Acitretina [spanish]

    27. Acitretin 100 Microg/ml In Acetonitrile:acetone

    28. 2,4,6,8-nonatetraenoic Acid, 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-e)-

    29. Acetretin

    30. 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid

    31. Soriatane Ck

    32. Soriatane (tn)

    33. Ccris 5534

    34. Ro-10-1670

    35. Hsdb 7187

    36. 419534-31-9

    37. Einecs 259-474-4

    38. Chebi:50172

    39. Unii-lch760e9t7

    40. U0279

    41. All-trans-etretin

    42. Acitretin [usan:usp:inn:ban]

    43. Acitretin,(s)

    44. Acitretin- Bio-x

    45. Acitretin (usp/inn)

    46. Acitretin [inn]

    47. Acitretin [mi]

    48. Acitretin [hsdb]

    49. Acitretin [usan]

    50. Spectrum5_002065

    51. Acitretin [vandf]

    52. Dsstox_cid_2553

    53. Acitretin [mart.]

    54. Acitretin [usp-rs]

    55. Acitretin [who-dd]

    56. Schembl3759

    57. Chembl1131

    58. Dsstox_rid_76624

    59. Dsstox_gsid_22553

    60. (2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic Acid

    61. Mls001076667

    62. Bidd:gt0617

    63. Gtpl7598

    64. Acitretin [orange Book]

    65. Acitretin [ep Monograph]

    66. Acitretin [usp Impurity]

    67. Dtxsid6022553

    68. Acitretin [usp Monograph]

    69. Bcpp000437

    70. Hms2234l17

    71. Hms3259j12

    72. Hms3714e17

    73. Acitretin, >=98.0% (hplc)

    74. Hy-b0107

    75. Zinc3798734

    76. Tox21_112012

    77. Bdbm50088429

    78. Mfcd00866632

    79. S1368

    80. Stl565770

    81. Akos015889991

    82. Ac-4702

    83. Bcp9000229

    84. Ccg-220668

    85. Cs-1855

    86. Db00459

    87. Ks-5246

    88. 2,4,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-

    89. Ncgc00163127-01

    90. Ncgc00163127-03

    91. (2e,4e,6e,8e)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic Acid

    92. (2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid

    93. As-12644

    94. Ba164136

    95. Smr000499573

    96. Cas-55079-83-9

    97. Cs-0368934

    98. Sw199134-2

    99. C75579

    100. D02754

    101. Ab00698376-08

    102. Ab00698376_09

    103. 079a839

    104. A830475

    105. Q341500

    106. Sr-01000763200

    107. Sr-01000763200-3

    108. Brd-k90699611-001-01-4

    109. Acitretin, British Pharmacopoeia (bp) Reference Standard

    110. Acitretin, European Pharmacopoeia (ep) Reference Standard

    111. Acitretin, United States Pharmacopeia (usp) Reference Standard

    112. Acitretin, Pharmaceutical Secondary Standard; Certified Reference Material

    113. 2,4,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2e,4e,6e,8e)-

    2.4 Create Date
    2005-03-27
    3 Chemical and Physical Properties
    Molecular Weight 326.4 g/mol
    Molecular Formula C21H26O3
    XLogP36.1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count6
    Exact Mass326.18819469 g/mol
    Monoisotopic Mass326.18819469 g/mol
    Topological Polar Surface Area46.5 Ų
    Heavy Atom Count24
    Formal Charge0
    Complexity539
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count4
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameAcitretin
    PubMed HealthAcitretin (By mouth)
    Drug ClassesAntipsoriatic
    Drug LabelAcitretin Capsules (acitretin), a retinoid, are available in 10 mg and 25 mg gelatin capsules for oral administration. Chemically, acitretin is all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid. It is a metabolite...
    Active IngredientAcitretin
    Dosage FormCapsule
    RouteOral
    Strength22.5mg; 25mg; 10mg; 17.5mg
    Market StatusPrescription
    CompanyTeva Pharms Usa; Barr Labs

    2 of 4  
    Drug NameSoriatane
    PubMed HealthAcitretin (By mouth)
    Drug ClassesAntipsoriatic
    Drug LabelSORIATANE (acitretin), a retinoid, is available in 10 mg, 17.5 mg, and 25 mg gelatin capsules for oral administration. Chemically, acitretin is all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid. It is a metabolite...
    Active IngredientAcitretin
    Dosage FormCapsule
    RouteOral
    Strength22.5mg; 25mg; 10mg; 17.5mg
    Market StatusPrescription
    CompanyStiefel Labs

    3 of 4  
    Drug NameAcitretin
    PubMed HealthAcitretin (By mouth)
    Drug ClassesAntipsoriatic
    Drug LabelAcitretin Capsules (acitretin), a retinoid, are available in 10 mg and 25 mg gelatin capsules for oral administration. Chemically, acitretin is all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid. It is a metabolite...
    Active IngredientAcitretin
    Dosage FormCapsule
    RouteOral
    Strength22.5mg; 25mg; 10mg; 17.5mg
    Market StatusPrescription
    CompanyTeva Pharms Usa; Barr Labs

    4 of 4  
    Drug NameSoriatane
    PubMed HealthAcitretin (By mouth)
    Drug ClassesAntipsoriatic
    Drug LabelSORIATANE (acitretin), a retinoid, is available in 10 mg, 17.5 mg, and 25 mg gelatin capsules for oral administration. Chemically, acitretin is all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid. It is a metabolite...
    Active IngredientAcitretin
    Dosage FormCapsule
    RouteOral
    Strength22.5mg; 25mg; 10mg; 17.5mg
    Market StatusPrescription
    CompanyStiefel Labs

    4.2 Therapeutic Uses

    Keratolytic Agents

    National Library of Medicine's Medical Subject Headings. Acitretin. Online file (MeSH, 2018). Available from, as of August 29, 2018: https://meshb.nlm.nih.gov/search

    /CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Acitretin is included in the database.

    NIH/NLM; ClinicalTrials.Gov. Available from, as of August 29, 2018: https://clinicaltrials.gov/

    Acitretin Capsules, USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, Acitretin Capsules, USP should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, Acitretin Capsules, USP should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments /Included in US product labeling/

    NIH; DailyMed. Current Medication Information for Acitretin Capsule (Updated: January 9, 2018). Available from, as of November 20, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6af396c2-af3e-436d-ba9a-583637495910

    Acitretin has been used in a limited number of patients for the management of discoid lupus erythematosus; efficacy was similar to that of hydroxychloroquine, but adverse effects were more severe and frequent with acitretin. Further study is needed to establish the role of acitretin in treating this condition. /NOT included in US product labeling/

    American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 3548

    For more Therapeutic Uses (Complete) data for Acitretin (9 total), please visit the HSDB record page.

    4.3 Drug Warning

    /BOXED WARNING/ CONTRAINDICATIONS AND WARNINGS: Pregnancy. Acitretin must not be used by females who are pregnant, or who intend to become pregnant during therapy or at any time for at least 3 years following discontinuation of therapy. Acitretin also must not be used by females who may not use reliable contraception while undergoing treatment and for at least 3 years following discontinuation of treatment. Acitretin is a metabolite of etretinate (TEGISON), and major human fetal abnormalities have been reported with the administration of acitretin and etretinate. Potentially, any fetus exposed can be affected. Clinical evidence has shown that concurrent ingestion of acitretin and ethanol has been associated with the formation of etretinate, which has a significantly longer elimination half-life than acitretin. Because the longer elimination half-life of etretinate would increase the duration of teratogenic potential for female patients, ethanol must not be ingested by female patients of childbearing potential either during treatment with acitretin or for 2 months after cessation of therapy. This allows for elimination of acitretin, thus removing the substrate for transesterification to etretinate. The mechanism of the metabolic process for conversion of acitretin to etretinate has not been fully defined. It is not known whether substances other than ethanol are associated with transesterification. Acitretin has been shown to be embryotoxic and/or teratogenic in rabbits, mice, and rats at oral doses of 0.6, 3, and 15 mg per kg, respectively. These doses are approximately 0.2, 0.3, and 3 times the maximum recommended therapeutic dose, respectively, based on a mg-per-m 2 comparison. Major human fetal abnormalities associated with acitretin and/or etretinate administration have been reported including meningomyelocele; meningoencephalocele; multiple synostoses; facial dysmorphia; syndactyly; absence of terminal phalanges; malformations of hip, ankle, and forearm; low-set ears; high palate; decreased cranial volume; cardiovascular malformation; and alterations of the skull and cervical vertebrae. Acitretin should be prescribed only by those who have special competence in the diagnosis and treatment of severe psoriasis, are experienced in the use of systemic retinoids, and understand the risk of teratogenicity. Because of the teratogenicity of acitretin, a program called P.P.E.T., Pregnancy Prevention is Essential with Treatment, has been developed to educate women of childbearing potential and their healthcare providers about the serious risks associated with acitretin and to help prevent pregnancies from occurring with the use of this drug and for 3 years after its discontinuation.

    NIH; DailyMed. Current Medication Information for Acitretin Capsule (Updated: January 9, 2018). Available from, as of November 20, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6af396c2-af3e-436d-ba9a-583637495910

    /BOXED WARNING/ Hepatotoxicity: Of the 525 subjects treated in US clinical trials, 2 had clinical jaundice with elevated serum bilirubin and transaminases considered related to treatment with acitretin. Liver function test results in these subjects returned to normal after acitretin was discontinued. Two of the 1,289 subjects treated in European clinical trials developed biopsy-confirmed toxic hepatitis. A second biopsy in one of these subjects revealed nodule formation suggestive of cirrhosis. One subject in a Canadian clinical trial of 63 subjects developed a 3-fold increase of transaminases. A liver biopsy of this subject showed mild lobular disarray, multifocal hepatocyte loss, and mild triaditis of the portal tracts compatible with acute reversible hepatic injury. The subject's transaminase levels returned to normal 2 months after acitretin was discontinued. The potential of therapy with acitretin to induce hepatotoxicity was prospectively evaluated using liver biopsies in an open-label trial of 128 subjects. Pretreatment and posttreatment biopsies were available for 87 subjects. A comparison of liver biopsy findings before and after therapy revealed 49 (58%) subjects showed no change, 21 (25%) improved, and 14 (17%) subjects had a worsening of their liver biopsy status. For 6 subjects, the classification changed from class 0 (no pathology) to class I (normal fatty infiltration; nuclear variability and portal inflammation; both mild); for 7 subjects, the change was from class I to class II (fatty infiltration, nuclear variability, portal inflammation, and focal necrosis; all moderate to severe); and for 1 subject, the change was from class II to class IIIb (fibrosis, moderate to severe). No correlation could be found between liver function test result abnormalities and the change in liver biopsy status, and no cumulative dose relationship was found. Elevations of AST (SGOT), ALT (SGPT), GGT (GGTP), or LDH have occurred in approximately 1 in 3 subjects treated with acitretin. Of the 525 subjects treated in clinical trials in the US, treatment was discontinued in 20 (3.8%) due to elevated liver function test results. If hepatotoxicity is suspected during treatment with acitretin, the drug should be discontinued and the etiology further investigated. Ten of 652 subjects treated in US clinical trials of etretinate, of which acitretin is the active metabolite, had clinical or histologic hepatitis considered to be possibly or probably related to etretinate treatment. There have been reports of hepatitis-related deaths worldwide; a few of these subjects had received etretinate for a month or less before presenting with hepatic symptoms or signs.

    NIH; DailyMed. Current Medication Information for Acitretin Capsule (Updated: January 9, 2018). Available from, as of November 20, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6af396c2-af3e-436d-ba9a-583637495910

    Acitretin is a known human teratogen, and there is a very high risk of severe birth defects if a patient becomes pregnant while receiving acitretin or upon drug discontinuance (birth defects have been reported 2 years or longer after the last dose of acitretin). Teratogenicity generally is characterized by malformations involving craniofacial, cardiovascular, skeletal, and CNS structures. Use of acitretin is contraindicated during pregnancy. The drug must not be used in female patients who are or may become pregnant during acitretin therapy or within at least 3 years following drug discontinuance or in females who may not use reliable contraception during and for at least 3 years following cessation of therapy. If pregnancy occurs during therapy or at any time for at least 3 years following drug discontinuance, the clinician and patient should discuss the possible effects on the pregnancy.

    American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 3549

    Acitretin is distributed into milk; women receiving the drug should not breast-feed.

    American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 3549

    For more Drug Warnings (Complete) data for Acitretin (20 total), please visit the HSDB record page.

    4.4 Drug Indication

    For the treatment of severe psoriasis in adults.

    FDA Label

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Acitretin is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within them) seen in psoriasis. It therefore reduces the thickening of the skin, plaque formation and scaling.

    5.2 MeSH Pharmacological Classification

    Keratolytic Agents

    Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. (See all compounds classified as Keratolytic Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    ACITRETIN
    5.3.2 FDA UNII
    LCH760E9T7
    5.3.3 Pharmacological Classes
    Retinoids [CS]; Retinoid [EPC]
    5.4 ATC Code

    D - Dermatologicals

    D05 - Antipsoriatics

    D05B - Antipsoriatics for systemic use

    D05BB - Retinoids for treatment of psoriasis

    D05BB02 - Acitretin

    5.5 Absorption, Distribution and Excretion

    Absorption

    Oral absorption of acitretin is optimal when given with food, and is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range 47% to 109%) of the administered dose was absorbed after a single 50 mg dose of acitretin was given to 12 healthy subjects.

    Route of Elimination

    Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted. The chain-shortened metabolites and conjugates of acitretin and cis-acitretin are ultimately excreted in the feces (34% to 54%) and urine (16% to 53%).

    /MILK/ Acitretin is distributed into milk ... .

    American Society of Health-System Pharmacists; Drug Information 2018. Bethesda, MD. 2018, p. 3549

    /MILK/ Retinoid transfer into breast milk was studied in a psoriatric woman receiving oral acitretin at a dosage of 40 mg once daily. Concentrations of the parent compound and its main metabolite, 13-cis acitretin, were measured in serum and mature milk during the initial nine days of therapy, using reverse-phase high performance liquid chromatography. At steady-state, trace amounts of the drug and metabolite (30-40 ng/mL) appeared in breast milk corresponding to a milk/serum concentration ratio of about 0.18. Acitretin was almost exclusively distributed in the fatty layers of the milk. Although the estimated amount of the drug consumed by a suckling infant would correspond to only 1.5% of the maternal dose, the toxic potential of acitretin justifies its avoidance in breast-feeding women.

    PMID:1981420 Rollman O, Pihl-Lundin I; Acta Derm Venereol 70 (6): 487-90 (1990)

    Oral absorption of acitretin is optimal when given with food. For this reason, acitretin was given with food in all of the following trials. After administration of a single 50-mg oral dose of acitretin to 18 healthy subjects, maximum plasma concentrations ranged from 196 to 728 ng per mL (mean: 416 ng per mL) and were achieved in 2 to 5 hours (mean: 2.7 hours). The oral absorption of acitretin is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range: 47% to 109%) of the administered dose was absorbed after a single 50-mg dose of acitretin was given to 12 healthy subjects.

    NIH; DailyMed. Current Medication Information for Acitretin Capsule (Updated: January 9, 2018). Available from, as of November 20, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6af396c2-af3e-436d-ba9a-583637495910

    Acitretin is more than 99.9% bound to plasma proteins, primarily albumin.

    NIH; DailyMed. Current Medication Information for Acitretin Capsule (Updated: January 9, 2018). Available from, as of November 20, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6af396c2-af3e-436d-ba9a-583637495910

    For more Absorption, Distribution and Excretion (Complete) data for Acitretin (7 total), please visit the HSDB record page.

    5.6 Metabolism/Metabolites

    Following oral absorption, acitretin undergoes extensive metabolism and interconversion by simple isomerization to its 13-cis form (cis-acitretin). Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted.

    Following oral absorption, acitretin undergoes extensive metabolism and interconversion by simple isomerization to its 13-cis form (cis-acitretin). The formation of cis-acitretin relative to parent compound is not altered by dose or fed/fast conditions of oral administration of acitretin. Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted. Following multiple-dose administration of acitretin, steady-state concentrations of acitretin and cis-acitretin in plasma are achieved within approximately 3 weeks.

    NIH; DailyMed. Current Medication Information for Acitretin Capsule (Updated: January 9, 2018). Available from, as of November 20, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6af396c2-af3e-436d-ba9a-583637495910

    ... In the presence of ethanol the ethyl esterification of acitretin to etretinate proceeds via formation of acitretinoyl-CoA.

    PMID:10874125 Knights KM et al; Biochem Pharmacol 60 (4): 507-16 (2000)

    5.7 Biological Half-Life

    49 hours (range 33 to 96 hours)

    ... 10 patients with severe psoriasis were treated with 30 mg acitretin daily for 3 months. ... After discontinuation of therapy, the rate of elimination of both acitretin (half life range 1.0 to 25.4 days) and 13-cis-acitretin (half life range 1.5 to 25.7 days) was found to be related to the observed mean steady-state level of etretinate as evidenced by a longer terminal half life of patients with high levels of etretinate in plasma. ...

    PMID:8491984 Larsen FG et al; J Invest Dermatol 100 (5): 623-7 (1993)

    The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).

    NIH; DailyMed. Current Medication Information for Acitretin Capsule (Updated: January 9, 2018). Available from, as of November 20, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6af396c2-af3e-436d-ba9a-583637495910

    5.8 Mechanism of Action

    The mechanism of action of acitretin is unknown, however it is believed to work by targeting specific receptors (retinoid receptors such as RXR and RAR) in the skin which help normalize the growth cycle of skin cells.

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"ACITRETIN","year":"2021","qtr":"Q1","strtotime":1616178600,"product":"ACITRETIN (OTHER)-(TAX INV VIPL\/0377 DT .28.02.2021 MFG GSTN 24AAACV8038L1Z2) PHARMACEUTICAL RAW MATERIALS","address":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"FAILSAN","customerCountry":"TURKEY","quantity":"24.02","actualQuantity":"24.02","unit":"KGS","unitRateFc":"4203.6","totalValueFC":"99927.9","currency":"USD","unitRateINR":302868,"date":"20-Mar-2021","totalValueINR":"7274889.36","totalValueInUsd":"99927.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"9506434","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1631903400,"product":"ACITRETIN(OTHER)(TAX INV VIPL\/0187 DT.","address":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TURKIYE VAKIFLAR BANKASI T,A,O-","customerCountry":"TURKEY","quantity":"24.02","actualQuantity":"24.02","unit":"KGS","unitRateFc":"4451.9","totalValueFC":"102411.1","currency":"USD","unitRateINR":313613.6552872606,"date":"18-Sep-2021","totalValueINR":"7533000","totalValueInUsd":"102411.1","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"4691188","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655490600,"product":"ACITRETIN (TAX INV NO: SPP2223-U1ES-019","address":"43-11-56, SUBBALAKSHMI NAGAR,RAILW AY NEW COLONY","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"SIONC PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA METROP","customer":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","customerCountry":"UNITED STATES","quantity":"9.88","actualQuantity":"9.875","unit":"KGS","unitRateFc":"5250","totalValueFC":"50887.5","currency":"USD","unitRateINR":402025.31645569619,"date":"18-Jun-2022","totalValueINR":"3970000","totalValueInUsd":"50887.5","indian_port":"HYDERABAD AIR","hs_no":"29332990","bill_no":"2221352","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"43-11-56, SUBBALAKSHMI NAGAR,RAILW AY NEW COLONY, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655922600,"product":"ACITRETIN (TAX INV NO: SPP2223-U1ES-022","address":"43-11-56, SUBBALAKSHMI NAGAR,RAILW AY NEW COLONY","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"SIONC PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA METROP","customer":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","customerCountry":"UNITED STATES","quantity":"19.83","actualQuantity":"19.825","unit":"KGS","unitRateFc":"5250","totalValueFC":"102287.6","currency":"USD","unitRateINR":402522.06809583859,"date":"23-Jun-2022","totalValueINR":"7980000","totalValueInUsd":"102287.6","indian_port":"HYDERABAD AIR","hs_no":"29332990","bill_no":"2330386","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"43-11-56, SUBBALAKSHMI NAGAR,RAILW AY NEW COLONY, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1661797800,"product":"ACITRETIN (OTHER) (LUT (ARN) NO AD2703","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BANGKOK","customer":"UBLACL","customerCountry":"THAILAND","quantity":"2.70","actualQuantity":"2.7","unit":"KGS","unitRateFc":"5220","totalValueFC":"13912.8","currency":"USD","unitRateINR":410000,"date":"30-Aug-2022","totalValueINR":"1107000","totalValueInUsd":"13912.8","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"3844218","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"THAILAND","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1688063400,"product":"ACITRETIN USP 41 (OTHER) (LUT (ARN) NO.A","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"FATEILSATIC","customerCountry":"TURKEY","quantity":"30.20","actualQuantity":"30.2","unit":"KGS","unitRateFc":"4140","totalValueFC":"118168.4","currency":"USD","unitRateINR":321622.52036423841,"date":"30-Jun-2023","totalValueINR":"9713000.115","totalValueInUsd":"118168.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1688063400,"product":"ACITRETIN USP 41 (OTHER) (LUT (ARN) NO.A","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"LIMA -","customer":"LAACFASA","customerCountry":"PERU","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"6030","totalValueFC":"22580.1","currency":"USD","unitRateINR":463999.94549999997,"date":"30-Jun-2023","totalValueINR":"1855999.782","totalValueInUsd":"22580.1","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PERU","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"ACITRETIN (TAX INV MH1160000484 DTD 09.01.2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UTTRLL","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"9230","totalValueFC":"657.6","currency":"EUR","unitRateINR":546550.5,"date":"17-Jan-2024","totalValueINR":"54655.05","totalValueInUsd":"657.6","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"6806076","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708367400,"product":"ACITRETIN USP 41 (OTHER) (LUT (ARN) NO.AD270323055216A) (TAX INV MH1160000543DTD.08.02.2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"FATEILSATIC","customerCountry":"TURKEY","quantity":"30.20","actualQuantity":"30.2","unit":"KGS","unitRateFc":"4000","totalValueFC":"117410.9","currency":"USD","unitRateINR":322583.66589403979,"date":"20-Feb-2024","totalValueINR":"9742026.71","totalValueInUsd":"117410.9","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"7666013","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711737000,"product":"ACITRETIN USP 41 (LUT(ARN)NO:AD270323055216A DT:27\/03\/2023) (TAX INV.NO:MH1160000624 DTD.16.03.2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"LIMA -","customer":"LAACFASA","customerCountry":"PERU","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"6030","totalValueFC":"16451.9","currency":"USD","unitRateINR":455364.51333333337,"date":"30-Mar-2024","totalValueINR":"1366093.54","totalValueInUsd":"16451.9","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"8784301","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PERU","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719599400,"product":"ACITRETIN USP 41 (OTHER)(LUT(ARN)NO: AD270324101144O DT: 15\/03\/2024)(TAX INV# MH2411600119 DT: 13\/06\/2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"LIMA -","customer":"LAACFASA.,,","customerCountry":"PERU","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"6030","totalValueFC":"16344.6","currency":"USD","unitRateINR":454812.66999999998,"date":"29-Jun-2024","totalValueINR":"1364438.01","totalValueInUsd":"16344.6","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"2069008","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PERU","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724869800,"product":"ACITRETIN USP 41 (OTHER)(LUT(ARN)NO: AD270324101144O DT: 15\/03\/2024)(TAX INV# MH2411600220 DT: 08.08.2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"LIMA -","customer":"LAACFASA.,,","customerCountry":"PERU","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"6030","totalValueFC":"16374.6","currency":"USD","unitRateINR":457825.3233333333,"date":"29-Aug-2024","totalValueINR":"1373475.97","totalValueInUsd":"16374.6","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"3576727","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PERU","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1626978600,"product":"ACITRETIN MICRO USP\/EP","address":"3RD FLOOR, PLOT NO.2, MAITRIVIHAR,","city":"HYDERABAD, ANDHRA PRADESH","supplier":"OLON S.P.A","supplierCountry":"ITALY","foreign_port":"N\/A","customer":"APL HEALTHCARE","customerCountry":"INDIA","quantity":"14.00","actualQuantity":"14","unit":"KGS","unitRateFc":"6907.7","totalValueFC":"97840.8","currency":"USD","unitRateINR":"520840","date":"23-Jul-2021","totalValueINR":"7291760","totalValueInUsd":"97840.8","indian_port":"APIIC MULTI PRODUCT SEZ NAIDUPET AP","hs_no":"29189990","bill_no":"1001033","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"DIREZIONE E UFFICI STR RIVOLTANA KM 6\/7 ITALY 20090","customerAddress":"3RD FLOOR, PLOT NO.2, MAITRIVIHAR,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643308200,"product":"ACITRETIN","address":"PLOT NO 54 AND 55 INDUSTRIAL AREA, PHASE 2","city":"CHANDIGARH,CHANDIGARH","supplier":"ADIA SHANGHAI PHARMA ","supplierCountry":"CHINA","foreign_port":"#N\/A","customer":"SCOTT-EDIL PHARMACIA","customerCountry":"INDIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2220","totalValueFC":"11220.2","currency":"USD","unitRateINR":"167166","date":"28-Jan-2022","totalValueINR":"835830","totalValueInUsd":"11220.2","indian_port":"DELHI AIR","hs_no":"29189990","bill_no":"7265600","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"PLOT NO 54 AND 55 INDUSTRIAL AREA, PHASE 2"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655317800,"product":"ACITRETIN MICRO USP\/EP(QTY: 2 KGS X 5800 EUR)","address":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET","city":"HYDERABAD","supplier":"OLON S.P.A","supplierCountry":"ITALY","foreign_port":"NA","customer":"AUROBINDO PHARMA LIMITED","customerCountry":"INDIA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"5800","totalValueFC":"12527","currency":"EUR","unitRateINR":"488650","date":"16-Jun-2022","totalValueINR":"977300","totalValueInUsd":"12527","indian_port":"HYDERABAD AIR","hs_no":"29189990","bill_no":"9137914","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1660847400,"product":"ACITRETIN ETHYL ESTER(INTERMEDIATE CHEMICALS)","address":"PLOT NO A1 2402 2 GIDC ESTATE,ANK LESHWAR","city":"BHARUCH,GUJARAT","supplier":"SUNERGY PHARMACHEM GROUP CO.","supplierCountry":"CHINA","foreign_port":"NA","customer":"JAY JALARAM ENTERPRISE","customerCountry":"INDIA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"2100","totalValueFC":"63738.6","currency":"USD","unitRateINR":"169050","date":"19-Aug-2022","totalValueINR":"5071500","totalValueInUsd":"63738.6","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"2072613","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO A1 2402 2 GIDC ESTATE,ANK LESHWAR"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709317800,"product":"ACITRETIN USP\/EP (QTY: 0.150 KGS, VALUE EUR: 1500)","address":"PLOT NO.2, MAITRIVIHAR,","city":"HYDERABAD\/ANDHRA PRADESH","supplier":"OLON S.P.A","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"AUROBINDO PHARMA LIMITED","customerCountry":"INDIA","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"10000","totalValueFC":"1637.5","currency":"EUR","unitRateINR":"906500","date":"02-Mar-2024","totalValueINR":"135975","totalValueInUsd":"1637.5","indian_port":"Hyderabad Air","hs_no":"29189990","bill_no":"2389897","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"STRADA RIVOLTANA KM 6\/7 20053 RODANO MI IT Rodano, ItalySDNF Italy","customerAddress":"PLOT NO.2, MAITRIVIHAR,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715970600,"product":"ACITRETIN EP (LICENSE NO. SW\/OD\/11\/2024\/000001694)","address":"MANISHA PLAZA SONAPUR LANE,","city":"MUMBAI,MAHARASHTRA","supplier":"CHONGQING HUAPONT SHENGCHEM PHARM CO., LTD.","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"ZIM LABORATORIES","customerCountry":"INDIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5500","totalValueFC":"28437.4","currency":"USD","unitRateINR":"474075.5","date":"18-May-2024","totalValueINR":"2370377.44","totalValueInUsd":"28437.4","indian_port":"Bombay Air","hs_no":"29189990","bill_no":"3553642","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO.666, RONGJUN ROAD, NANJIN AVENUE,HECHUAN DISTRICTSDNF CHINA","customerAddress":"MANISHA PLAZA SONAPUR LANE,"}]
    20-Mar-2021
    29-Aug-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE;ORAL - 10MG **Federal Regist...DOSAGE - CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19821

    read-more

    DOSAGE - CAPSULE;ORAL - 17.5MG **Federal Regi...DOSAGE - CAPSULE;ORAL - 17.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19821

    read-more

    DOSAGE - CAPSULE;ORAL - 22.5MG **Federal Regi...DOSAGE - CAPSULE;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19821

    read-more

    DOSAGE - CAPSULE;ORAL - 25MG **Federal Regist...DOSAGE - CAPSULE;ORAL - 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19821

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Granulation

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Topical

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search